

# Pharmaxis Ltd

01:17 12 Sep 2019

## Pharmaxis features in APAC's top 100 most innovative pharma companies report

Pharmaxis Ltd (ASX:PXS) has been included in a new report which ranks the company among the top 100 most innovative pharma companies in the Asia Pacific (APAC) region.

The report was prepared by Cortellis and is entitled "Pharmaceutical innovation in the APAC region".

It studied a cohort of 929 companies including multi-nationals across 14 countries/regions that have or are developing innovative pharmaceutical products.

Fourteen Australian companies featured in the top-100 and Pharmaxis was the second-highest ranked of the 14.

### Translating R&D into results

Pharmaxis' CEO Gary Phillips said: "I'm delighted but not surprised that Pharmaxis has been recognised in this report, the first of its kind.

"We have clearly met key indicators such as being able to demonstrate a strong pipeline and translate our R&D into actual drug candidates.

"Early stage partnering was also a measure studied for the report and Pharmaxis has made this a key business objective."

### Track record of delivering value

The company's ability to create value for shareholders through R&D is best exemplified by its 2015 deal with Boehringer.

Pharmaxis sold its anti-inflammatory drug candidate to Boehringer in a deal structured to deliver potential value in excess of \$A750 million.

The Pharmaxis drug discovery team has moved four drugs into the clinic over the last five years.

The company's pipeline is focused on anti-fibrotic agents to treat a variety of diseases through inhibiting the LOX and LOXL2 enzymes.

The LOXL2 inhibition program is currently in a commercial partnering process.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

No investment advice

**Price:** 0.077

**Market Cap:** \$30.43 m

### 1 Year Share Price Graph



### Share Information

**Code:** PXS

**Listing:** ASX

**52 week High Low**  
**0.285 0.053**

**Sector:** Pharma & Biotech

**Website:** [www.pharmaxis.com.au](http://www.pharmaxis.com.au)

### Company Synopsis:

*Pharmaxis Ltd (ASX:PXS) is a specialty pharmaceutical company focused on the development of new products for the diagnosis and treatment of chronic respiratory and immune disorders.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).